The CAS Content Collection 66 is the largest human-compiled collection of published scientific information, which represents a valuable resource to access and keep up to date on the scientific literature all over the world across disciplines including chemistry, biomedical sciences, engineering, materials science, agricultural science, and many more, thus allowing quantitative analysis of global research publications across various parameters including time, geography, scientific area, medical application, disease, and chemical composition. Currently, there are over 300,000 scientific publications (mainly journal articles and patents) in the CAS Content Collection related to the AD, including over 250,000 articles in scientific journals and nearly 50,000 patents. There has been a steady growth of these documents over the last three decades, with an >30% increase in the last three years (2021-2023) (Figure ). The journal articles largely dominate, showcasing the intense research in the area. The relative growth in the number of documents related to the AD as well as the journal/patent number ratio virtually coincides with that for the overall class of neurodegenerative diseases during the last two decades (Figure ) which is understandable since AD is by far the most prevalent and most widely explored disease in that class of diseases. The high journal/patent number ratio with regards to the AD research in the 1990s reflect the initial period of knowledge accumulation preceding the subsequent opportunities for commercialization. USA, China, Japan, Germany, and South Korea are the leaders with respect to the number of published journal articles and patents related to AD research (Figure ). The Alzheimer's Disease Neuroimaging Initiative, University of California, Harvard Medical School, and the Chinese Academy of Sciences are the leaders with respect to the number of published journal articles related to the AD (Figure ). Patenting activity is dominated by corporate players as compared to academics (Figure ). F. Hoffmann-La Roche, Merck, Pfizer, and AstraZeneca have the highest number of patent applications among the companies (Figure ), while University of California, Centre national de la recherche scientifique (CNRS, France), and Korea Institute of Science & Technology lead among the non-commercial organizations (Figure ). The most patent applications have been filed at the World Intellectual Property Organization (WIPO) followed by the US and China patent offices (Figure ). Journal of Alzheimer's Disease is a distinct leader with respect to the number of published articles related to Alzheimer's disease research, followed by Neurobiology of Aging, Neurology, and PLoS One (Figure ). With respect to the substance classes explored in the AD-related documents in CAS Content Collection, the largest part belong to the organic & inorganic small molecules (Figure ).